Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2022 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks: does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago? We need to look for any statement in the transcript where management compares the size/scope of current engagements to past ones for the same offering, indicating escalation of unit size. Scanning the transcript: The call is about Cue Biopharma's clinical trials, particularly CUE-101 and CUE-102. They discuss data from monotherapy and combination trials. They talk about expansion cohorts, registrational trials, etc. But the question is about "deals, orders, contracts, projects, customers, sites, or programs" - in this context, it might refer to clinical trial sites, patient enrollment, or perhaps partnerships? But the transcript is mostly about clinical data and pipeline. Management mentions "expansion cohort" and "registrational trial" but that's about trial design, not about the size of engagements like contracts or deals. They also mention "CUE-102" trial opening at 15 sites. But is there any statement about the size of these engagements increasing over time? For example, are they saying that the current trials are larger than previous ones? Or that they are enrolling more patients? That would be volume, not unit size. The question specifically asks about "successive engagements of the same kind" - meaning the same type of business (e.g., clinical trials, partnerships, etc.) coming in at progressively larger size. For instance, if they say "our latest trial has more sites than our previous trial" that would be escalation. But I don't see that. They mention "CUE-102" is a new trial, but it's a different drug. They also mention "NeoStat" as a platform expansion, but that's not about the same offering. Look for any comparison like "we are now seeing larger orders" or "our customers are starting at a higher level" etc. Not present. The transcript is about clinical data, survival, response rates, etc. No mention of deals or contracts. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.